Avita Therapeutics (Australia) Today
| AVH Stock | 3.90 0.04 1.02% |
Performance14 of 100
| Odds Of DistressLess than 50
|
Avita Therapeutics is selling for under 3.90 as of the 30th of November 2024; that is 1.02 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 3.85. Avita Therapeutics has 50 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. Equity ratings for Avita Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Avita Therapeutics is entity of Australia. It is traded as Stock on AU exchange. The company has 129.95 M outstanding shares. More on Avita Therapeutics
Moving together with Avita Stock
Moving against Avita Stock
Follow Valuation Profit Patterns Daily Balance Of Power
Check how we calculate scores
Avita Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Avita Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Avita Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | James Corbett | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
Avita Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Avita Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsAvita Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Avita Therapeutics' financial leverage. It provides some insight into what part of Avita Therapeutics' total assets is financed by creditors.
| |||||
Avita Therapeutics (AVH) is traded on Australian Securities Exchange in Australia and employs 207 people. Avita Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 504.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Avita Therapeutics's market, we take the total number of its shares issued and multiply it by Avita Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Avita Therapeutics operates under Biotechnology sector and is part of Health Care industry. The entity has 129.95 M outstanding shares.
Avita Therapeutics has accumulated about 55.51 M in cash with (38.01 M) of positive cash flow from operations.
Check Avita Therapeutics Probability Of Bankruptcy
Ownership AllocationAvita Therapeutics holds a total of 129.95 Million outstanding shares. Almost 99.83 percent of Avita Therapeutics outstanding shares are held by general public with 0.17 (percent) owned by insiders and only 0.0 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Avita Ownership Details
Avita Therapeutics Risk Profiles
Although Avita Therapeutics' alpha and beta are two of the key measurements used to evaluate Avita Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.63 | |||
| Semi Deviation | 2.54 | |||
| Standard Deviation | 3.28 | |||
| Variance | 10.75 |
Avita Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Avita Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Avita Therapeutics Corporate Management
Elected by the shareholders, the Avita Therapeutics' board of directors comprises two types of representatives: Avita Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avita. The board's role is to monitor Avita Therapeutics' management team and ensure that shareholders' interests are well served. Avita Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avita Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rob Hall | Senior Resources | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Jessica Ekeberg | Investor Executive | Profile | |
| David OToole | Chief Officer | Profile | |
| Kathy McGee | Chief Officer | Profile | |
| Terry Bromley | Senior Sales | Profile |
Additional Tools for Avita Stock Analysis
When running Avita Therapeutics' price analysis, check to measure Avita Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avita Therapeutics is operating at the current time. Most of Avita Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avita Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avita Therapeutics' price. Additionally, you may evaluate how the addition of Avita Therapeutics to your portfolios can decrease your overall portfolio volatility.